EuroNet-PHL-C2 Second trial conducted by European experts in the field for treating Classical Hodgkin’s Lymphoma in Children and Adolescents (Aktiv)
Zweitlinie oder später
AERN Abskopaler Effekt von Radiotherapie und Nivolumab bei anti-PD1 vorbehandeltem rezidiviertem oder refraktärem Hodgkin-Lymphom (HL) (Aktiv)
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
HD 21 Treatment optimization Trial in the first-line Treatment of advanced stage Hodgin-Lymphoma (Aktiv)
MK7684A-004 Phase II Studie zu MK-7684A (Vibostolimab/Pembrolizumab) bei rezidivierenden/refraktären hämatologischen Krebserkrankungen (Aktiv)